Vivos Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue was approximately $6.4 million, down approximately $0.4 million or 5% from $6.8 million in the third quarter of 2025; service revenue increased 1% to approximately $4.6 million, while product revenue decreased approximately $0.4 million to approximately $1.8 million.
- For the nine months ended September 30, 2026, revenue increased approximately $3.1 million or 23% to $16.7 million, driven by a 57% increase in service revenue, partly offset by a $1.3 million decline in product revenue.
- Third-quarter gross profit was $3.3 million and gross margin was 52%, compared with 58% in the third quarter of 2025; nine-month gross profit increased 23% to $9.3 million and gross margin rose to 56% from 55%.
- Third-quarter general and administrative expenses declined 18% to approximately $6.5 million, and sales and marketing expenses declined 48% to approximately $0.2 million; operating loss improved by $0.8 million or 18% to $3.9 million.
- Net loss was $2 million for the third quarter of 2026, including an approximately $2.9 million benefit from reversing the previously recorded Employee Retention Credit liability; nine-month net loss was $15.2 million.
- As of September 30, 2026, Vivos had approximately $0.2 million in cash and cash equivalents, $20.7 million in total liabilities, and approximately $2.3 million of outstanding principal under its Streeterville Capital senior secured note, due June 10, 2027; management said cash was insufficient to fund operations and strategic objectives over the next 12 months and that substantial doubt existed about the company’s ability to continue as a going concern without additional financing.
- On October 16, 2026, Vivos completed the SOD Sciences transaction, issuing 12,000 shares of Series C convertible preferred stock in exchange for an equity interest in SOD Sciences and a 50% co-ownership interest in its pseudohypoxia early warning test and related intellectual property.
- Vivos said it had eliminated over $5 million in annual operating costs; Nasdaq notified the company on October 20, 2026, that it had regained compliance with the stockholders’ equity requirement, subject to continued monitoring, while it remained out of compliance with the $1 minimum bid price requirement and had a compliance period through December 4, 2026.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, everyone, and welcome to the Vivos Therapeutics Third Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. This conference call is being recorded, and a replay of today's call will be available on the Investor Relations section of Vivos' website and will remain posted there for the next 30 days. I will now hand the call over to Roman Franklin, Vivos' Chief Financial Officer, for introductions and the reading of the safe harbor statement.
Please go ahead. Thank you, operator.
Hello, everyone, and welcome to our conference call. A copy of our earnings press release is available on the Investor Relations section of our website at www.vivos.com. With me on the call is Kirk Huntsman, Vivos' Chairman and Chief Executive Officer. Today, we'll review the financial results for the third quarter of 2026, as well as more recent developments and Vivos' plans for the rest of 2026 and beyond. Our earnings press release published today compares mainly the third quarter of 2026 against the second quarter of 2026 to highlight the impact of our efforts to increase revenue and cut costs. You should review the earnings press release together with our quarterly reports on Form 10-Q for the quarters ended September 30, 2026, and June 30, 2026.
I would also like to remind everyone that today's call will contain certain forward-looking statements from our management made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning future events and our future financial and operating performance. Words such as aim, may, could, should, projects, expects, intends, plans, believes, anticipates, hopes, estimates, goal, and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant risk, uncertainties, and contingencies, many of which are beyond the company's control.
Actual results, including without limitation, the results of Vivos' growth strategies, operational plans, including sales, marketing, distribution, medical sleep provider acquisition and integration, research and development, regulatory initiatives, cost savings plans, and plans to generate revenue, as well as future potential results of operations or operating metrics, such as the potential for Vivos to achieve future positive cash flows or profitability, and other matters to be addressed by Vivos management in this conference call, may differ materially and adversely from those expressed or implied by such forward-looking statements.
Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described and other disclosures contained in Vivos' filings with the Securities and Exchange Commission, including the risk factors and other disclosures in our Form 10-K for the year ended December 31, 2025, and our other filings with the SEC, including our third quarter 10-Q filed with the SEC today, all of which are or will be accessible on the Investor Relations section of Vivos' website, as well as the SEC's website. Forward-looking statements speak only as of the date of this call. Except to the extent required by law, Vivos assumes no obligation to update statements as circumstances change. Finally, please be aware that the U.S. Food and Drug Administration has given certain specific Vivos appliances 510(k) clearance to treat mild to severe obstructive sleep apnea in adults.
With the FDA clearance of certain Vivos products for severe OSA in November 2023, treatment of patients with severe OSA with these specific appliances no longer need to be performed off-label at the clinical discretion of the treating doctor and is now an integral part of the Vivos treatment protocol. Treatment of OSA of any severity or any other condition with any other of Vivos' FDA-cleared devices remains at the clinical discretion of the treating doctor. For further information on our results for the three and nine-month periods ended September 30, 2026, please see our earnings release, which was distributed earlier today, and our quarterly reports on Form 10-Q, which are available on the SEC filings portion of the Investor Relations section of our website.
In the third quarter of 2026, Vivos completed its fifth full quarter of activity following our June 10, 2025 acquisition of The Sleep Center of Nevada. This is the first quarter in which our year-over-year comparison includes a full quarter of SCN operations in both periods. During the quarter, we remained focused on reducing operating costs, strengthening our balance sheet, and building the clinical lines we believe will drive revenue and margin going forward. Revenue decreased by approximately $0.4 million or 5% to approximately $6.4 million for the three months ended September 30, 2026, compared to $6.8 million for the three months ended September 30, 2025, which was our first full quarter following the SCN acquisition.
Product revenue decreased by approximately $0.4 million to approximately $1.8 million, reflecting lower appliance sales to our VIPs as a result of our strategic pivot away from VIPs to sleep centers, while service revenue increased by 1% to approximately $4.6 million. For the nine months ended September 30, 2026, revenue increased by approximately $3.1 million or 23% to $16.7 million compared to $13.6 million for the nine months ended September 30, 2025. The increase in total revenue during the period was driven by an increase of approximately $4.4 million or 57% in service revenue, offset by a decrease of approximately $1.3 million in product revenue.
The decrease in product revenue was attributable to lower sales volume of our on-demand orthodontic devices to VIP members, again, due to our strategic pivot, while the increase in service revenue reflects new patients being treated at our Sleep and Airway Medicine Centers in Las Vegas and Henderson, Nevada. Cost of sales increased $0.3 million or 9% to approximately $3.1 million for the three months ended September 30, 2026, compared to $2.8 million for the three months ended September 30, 2025. This is primarily attributable to higher costs associated with diagnostic services and patient therapy, including the addition of staff at the Vivos treatment centers. For the nine months ended September 30, 2026, cost of sales increased $1.3 million or 22% to $7.4 million compared to $6.1 million for the nine months ended September 30, 2025.
This is primarily related to higher costs associated with diagnostic services and patient therapy, including the addition of staff at the Vivos treatment centers. For the three months ended September 30, 2026, gross profit decreased by approximately $0.6 million to $3.3 million. This decrease was attributable to the decrease in revenue of approximately $0.4 million and the increase in cost of sales of $0.3 million. Gross margin decreased to 52% for the three months ended September 30, 2026, compared to 58% for the three months ended September 30, 2025, due to the decrease in product revenue. For the nine months ended September 30, 2026, gross profit increased by $1.8 million or 23% to $9.3 million. This increase is attributable to the increase in revenue of $3.1 million, partially offset by the increase in cost of sales of $1.3 million.
Gross margin increased to 56% for the nine months ended September 30, 2026, compared to 55% for the nine months ended September 30, 2025. General and administrative expenses decreased $1.4 million or 18% to approximately $6.5 million for the three months ended September 30, 2026, as compared to $7.9 million for the three months ended September 30, 2025. The decrease is primarily attributable to a $0.8 million reduction in professional fees, a $0.3 million reduction in equipment maintenance, a $0.2 million decrease in office expenses and supplies, and a $0.1 million decrease in infrastructure expenses. This reflects our continued focus on cost reduction and the absence of certain integration costs incurred in the prior year period following the acquisition of SCN.
For the nine months ended September 30, 2026, general and administrative expenses increased by $3.4 million or 17% to $22.5 million as compared to $19.2 million for the nine months ended September 30, 2025. The primary driver of this increase related to the costs associated with establishing our two Sleep and Airway Medicine Centers in Las Vegas and Henderson, Nevada, including an increase in salaries and related compensation of $1.7 million, an increase of $0.9 million in professional fees, an increase in occupancy expenses of $0.6 million, and other costs of $0.3 million. Sales and marketing expenses decreased $0.2 million or 48% to approximately $0.2 million for the three months ended September 30, 2026, as compared to $0.4 million for the three months ended September 30, 2025, which is attributable in significant part to our focus on reducing costs.
Sales and marketing expenses decreased by $0.4 million to $0.6 million for the nine months ended September 30th, 2026, compared to $1 million for the nine months ended September 30th, 2025. This decrease was primarily driven by our decrease in sales and marketing campaigns, lower commissions paid to our employees for digital media services, and reduction in use of marketing supplies. The depreciation and amortization expense increased $0.2 million for the three months ended September 30th, 2026, and increased $0.6 million to $1.5 million for the nine months ended September 30th, 2026, from $0.9 million for the nine months ended September 30th, 2025. Depreciation and amortization increased due to assets being placed into service during the period.
Other expense increased $0.3 million for the quarter and $2.3 million year to date, primarily due to interest expense, including interest expense on short-term financing agreements entered into in the third quarter. This was more than offset by an increase in other income of $2.9 million for the quarter and $3.2 million year to date. The increase in other income is primarily attributable to the reversal of our previously recorded Employee Retention Credit liability of approximately $2.9 million. Management concluded that repayment of the credits is no longer deemed probable. Year to date, other income also includes $0.3 million related to the valuation change and the earnout related to the acquisition of SCN. The financial statements have been prepared in conformity with generally accepted accounting principles, which contemplates continuation of the company as a going concern.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
